Abstract
Up to 70 % of newly diagnosed patients with advanced prostate cancer (PCa) will progress to castration-resistant prostate cancer (CRPC) and, in most cases (from 50 to 70 %), will develop hematogenous bone metastasis. Once PCa cells spread to the skeleton, cancer-related death becomes inevitable, with a death burden of more than 28,000 cases in 2012, in the United States (Semenas et al, Curr Drug Target, 13(10):1308–1323, 2012).
To date, therapeutic regimens are unable to revert this fatal progression (Semenas et al, Curr Drug Target, 13(10):1308–1323, 2012).
Thus, PCa bone metastatic prostate cancer still represents a major clinical challenge.
Prostate cancer biology is tightly linked to AR, which regulates epithelial proliferation and suppresses apoptosis both in normal and in cancer prostate tissue, and is involved in the progression of the disease toward a castration-resistant state (Hodgson et al, World J Urol, 30(3):279–285, 2012). Our knowledge of the molecular mechanisms, responsible for the acquired resistance to ADT in prostate cancer, has exponentially progressed during the last years. For instance, we have recently learnt that it may be associated with the occurrence of AR splicing variants (Hu et al. 2011).
Surgical castration has shown to induce regression of advanced disease 40-years before the cloning of androgen receptor (AR) (Huggins et al, Arch Surg, 43:209–223, 1941; Lubahn et al, Science, 240:327–330, 1988).
Since then, hormonal therapy was held over as the main available therapeutic option for aggressive prostate cancers. In the last decade, however, chemotherapy was introduced to targeting the epithelium of metastatic, hormone-resistant prostate cancer (Pinto et al, Tumour Biol, 33(2):421–426, 2012; Hodgson et al, World J Urol, 30(3):279–285, 2012). The cytotoxic conventional drug Docetaxel was approved by the Food and Drug Administration in 2004, and still represents the standard first-line treatment for patients with castration-resistant prostate cancer (CRPC) (Sartor et al, Oncologist, 16(11):1487–1497, 2011). It produces sensible palliative effects on bone-metastasis-related symptoms, but prolongs only modestly the survival of patients (Hodgson et al, World J Urol, 30(3):279–285, 2012; Tannock et al, N Engl J Med, 351:1502–1512, 2004; Petrylak et al, N Engl J Med, 351:1513–1520, 2004). Docetaxel acts mainly by inducing apoptosis of target epithelial cells. The common intrinsic defects of mCRPC in apoptosis pathways, such as BCL-2 overexpression and/or phosphatase and tensin homolog (PTEN) loss (Mathew, Dipaola, J Urol, 178:S36–S41, 2007; Galsky, Vogelzang, Ann Oncol, 21:2135–2144, 2010), may constitute the rationale of the unsatisfactory rate of cure attributable to this drug (Srigley et al, Histopathology, 60(1):153–165, 2012). In recent years, similar effects on survival have been demonstrated also for several other chemotherapeutic agents, such as mitoxantrone, etoposide, cisplatinum, vinblastine–estramustine and taclitaxel.
Following progression after treatment with docetaxel, new cabazitaxel (XRP6258)-prednisone treatment regimens have led to a significantly longer overall survival, and other novel agents are currently being evaluated, including the cell-based immunotherapy sipuleucel-T, the androgen biosynthesis inhibitors abiraterone acetate and MDV3100, the chemotherapic Cabazitaxel, as well as the radionuclide alpharadin/Radium 223 (bone microenvironment targeting agents) (Sartor et al, Oncologist, 16(11):1487–1497, 2011; Liu et al, Front Endocrinol (Lausanne), 3:72, 2012; Antonarakis, Armstrong, Prostate Cancer Prostatic Dis, 14(3):206–218, 2011). To date, they seem to offer a survival advantage to patients, and look promising to improve the prognosis of metastatic CRPC.
However, the real clinical benefit of these systemic therapies remains still transient, probably due also to the well-known clonal heterogeneity of advanced prostate cancers, and the overall survival of patients that holds frustratingly steady.
The high cost of these therapies and the increasing complexity of clinical decision making, further underscore the need to multiply the efforts to develop more potent chemotherapy agents and/or novel AR/inhibitors agents that may better overcome resistance mechanisms to existing therapies (Liu et al, Front Endocrinol (Lausanne), 2012; Hodgson et al, World J Urol, 30(3):279–285, 2012; Armstrong, George, Urol Oncol, 26:430–437, 2008; Schrijvers et al, Adv Ther, 27:285–296, 2010).
Several recently developed drug candidates, directed against the metastatic cancer microenvironments or niches, show promising results in this direction (Hodgson et al, World J Urol, 30(3):279–285, 2012).
The efficacy of the standard-of-care therapeutic intervention directed to mCRPC will be greatly improved by our increasing understanding of molecular mechanisms of the acquired resistance to ADT and chemotherapy, which is expected to provide valuable insights also to new unfailing biomarkers of resistance, therapeutic response and disease progression of prostate cancer, allowing us to personalize the therapy for the single patients with mCRPC (Liu et al, Front Endocrinol (Lausanne), 3:72, 2012; Antonarakis and Armstrong, Prostate Cancer Prostatic Dis, 14(3):206–218, 2011).
The knowledge of the molecular mechanisms underpinning prostate cancer progression is changing dramatically our therapeutic approach to its advanced, metastasizing phase, opening up the chance to design and develop novel agents targeting the multiple pathways responsible for the lethal cancer phenotype, in a more efficient and safer manner (Corcoran and Gleave, Histopathology, 60(1): 216–231, 2012).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Agarwal N, Sonpavde G, Sternberg CN (2012) Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol 61(5):950–960. Epub 2011 Dec 22
Antolín AR, Ojeda JM, Otero JR, Rodríguez AC, Castellano D, Esteban MD, Sicilia LD, González RD (2012) Hormonal treatment in biochemical recurrence after radical prostatectomy. Arch Esp Urol 65(1):111–121. Review. Spanish
Antonarakis ES, Armstrong AJ (2011) Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 14(3):206–218. Epub 2011 May 17. Review
Araujo J, Logothetis C (2010) Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 36:492–500
Armas OA, Aprikian AG, Melamed J et al (1994) Clinical and pathological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18:979–991
Armstrong AJ, George DJ (2008) New drug development in metastatic prostate cancer. Urol Oncol 26:430–437
Batist G (2007) Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol 7:72–74
Beekman KW, Hussain M (2008) Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient. Urol Oncol 26(4):415–419
Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM (2004) Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 91:1425–1427
Berthold DR, Sternberg CN, Tannock IF (2005) Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23:8247–8252
Bradley DA, Hussain M (2008) Promising novel cytotoxic agents and combinations in metastatic prostate cancer. Cancer J 14(1):15–19. Review
Bullock MJ, Srigley JR, Klotz LH et al (2002) Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma. A detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 26:1400–1413
Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959–1966
Chi KN, Zoubeidi A, Gleave ME (2008) Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drug 17:1955–1962
Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT (1995) Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46(6):849–855
Civantos F, Marcial MA, Banks ER et al (1995) Pathology of androgen deprivation therapy in prostate carcinoma: a comparative study of 173 patients. Cancer 75:1634–1641
Cook RJ, Coleman R, Brown J et al (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12:3361–3367
Corcoran NM, Gleave ME (2012) Targeted therapy in prostate cancer. Histopathology 60(1):216–231
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351(15):1488–1490
Dias-Santagata D, Akhavanfardy S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, John A (2010) Iafrate Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146–158
El-Amm J, Aragon-Ching JB (2013) The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 5(1):25–40
el-Rayes BF, Hussain MH (2002) Hormonal therapy for prostate cancer: past, present and future. Expert Rev Anticancer Ther 2(1):37–47
Evans AJ, Ryan P, van der Kwast T (2011) Treatment effects in the prostate including those associated with traditional and emerging therapies. Adv Anat Pathol 18:281–293
Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31:161–181
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45. Review
Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–882
Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419–436
Galsky MD, Vogelzang NJ (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21:2135–2144
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892. Erratum in: N Engl J Med. 2012 Sep 6;367(10):976
Gleave ME, Miyake H, Zellweger T et al (2001) Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 58:39–49
Growcott JW (2009) Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drug 20:83–88
Guise TA, Yin JJ, Mohammad KS (2003) Role of endothelin-1 in osteoblastic bone metastases. Cancer 97:779–784
Hodgson MC, Bowden WA, Agoulnik IU (2012) Androgen receptor footprint on the way to prostate cancer progression. World J Urol 30(3):279–285. Epub 2011 Sep 17. Review
Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate. 71(15):1656–1667
Huggins C, Hodges CV (1941) Studies on prostatic cancer: (1) the effect of estrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res 1:293–297
Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer: (II) the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223
Humphrey PA (2003) Prostate pathology. American Society for Clinical Pathology, Chicago, pp 456–476
July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50:179–188
Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, Archimandritis S, Karkavitsas NN (2000) High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas–rationale for combination with radiotherapy. Acta Oncol 39:207–211
Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF (2013) Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol. 31(5):549–556
Lee LF, Guan J, Qiu Y, Kung HJ (2001) Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk⁄Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21:8385–8397
Lee LF, Louie MC, Desai SJ et al (2004) Interleukin-8 confers androgenindependent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23:2197–2205
Liu Y, Hegde P, Zhang F, Hampton G, Jia S (2012) Prostate cancer – a biomarker perspective. Front Endocrinol (Lausanne) 3:72
Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM (1988) Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240:327–330
Mathew P, Dipaola R (2007) Taxane refractory prostate cancer. J Urol 178:S36–S41
Mathew P, Thall PF, Bucana CD et al (2007) Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13:5816–5824
Mita AC, Denis LJ, Rowinsky EK et al (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723–730
Miyake H, Nelson C, Rennie PS, Gleave ME (2000) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60:170–176
Mohler JL (2008) A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 22(2):357–372. Review
Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447–4454
Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178(4 Pt 1):1290–1295
Mostaghel EA, Montgomery B, Nelson PS (2009) Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 27(3):251–257
NCCN (National Comprehensive Cancer Network) (2011) Guidelines for Patientes. Proste cancer, Version 1
Nelson JB, Chan-Tack K, Hedican SP et al (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663–668
Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110–116
Park SI, Shah AN, Zhang J, Gallick GE (2007) Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Target 11:1207–1217
Park SI, Zhang J, Phillips KA et al (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68:3323–3333
Petraki CD, Sfikas CP (2007) Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 1:107–118
Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12(6):1665–1671
Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E (2012) Targeting the endothelin axis in prostate carcinoma. Tumour Biol 33(2):421–426. Epub 2011 Dec 29
Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468
Sartor O, Michels RM, Massard C, de Bono JS (2011) Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 16(11):1487–1497. Epub 2011 Nov 2.Review
Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253–8261
Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M (1997) Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15(8):2928–2938
Schrijvers D, Van Erps P, Cortvriend J (2010) Castration-refractory prostate cancer: new drugs in the pipeline. Adv Ther 27:285–296
Schwarz EM, Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9(suppl 1):S7
Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL (2012) Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Target 13(10):1308–1323. Review
Srigley JR, Delahunt B, Evans AJ (2012) Therapy-associated effects in the prostate gland. Histopathology 60(1):153–165
Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18(9):1359–1368
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
Taplin ME (2008) Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 8(9):1495–1508. Review
Têtu B (2008) Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma. Best Pract Res Clin Endocrinol Metab 22:271–283
Têtu B, Srigley JR, Boivin JC et al (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 15:111–120
Tiligada E, Miligkos V, Delitheos A (2002) Cross-talk between cellular stress, cell cycle and anticancer agents: mechanistic aspects. Curr Med Chem Anticancer Agent 2:553–566
Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C (2005) Casodex’ Early Prostate Cancer Trialists Group. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 76(1):4–10
Vallancourt L, Têtu B, Fradet Y et al (1996) Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am J Surg Pathol 20:86–93
Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME (2001) Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3:360–367
Zellweger T, Chi K, Miyake H et al (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8:3276–3284
Zoubeidi A, Chi K, Gleave M (2010) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16:1088–1093
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Staibano, S. (2013). Resistance to Castration – Resistance to Drugs. In: Staibano, S. (eds) Prostate Cancer: Shifting from Morphology to Biology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7149-9_7
Download citation
DOI: https://doi.org/10.1007/978-94-007-7149-9_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7148-2
Online ISBN: 978-94-007-7149-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)